Free tool
FAERS Monitor: Ultravate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208183 or its brand name (Ultravate, Halobetasol Propionate). Reports on generic versions are filed under their own applications.
Reports
1,220
Serious
441
36% of reports
Hospitalization
170
Death reported
28
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective253
- psoriasis167
- pruritus113
- product use in unapproved indication87
- rash80
- pain72
- fatigue68
- arthralgia65
- dry skin54
- cough51
- off label use50
- skin exfoliation49
- diarrhoea48
- nausea48
- condition aggravated46
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 23 |
| 2005 | 23 |
| 2006 | 22 |
| 2007 | 14 |
| 2008 | 4 |
| 2009 | 11 |
| 2010 | 7 |
| 2011 | 15 |
| 2012 | 19 |
| 2013 | 21 |
| 2014 | 23 |
| 2015 | 49 |
| 2016 | 77 |
| 2017 | 52 |
| 2018 | 56 |
| 2019 | 60 |
| 2020 | 71 |
| 2021 | 76 |
| 2022 | 146 |
| 2023 | 233 |
| 2024 | 86 |
| 2025 | 70 |
| 2026 | 62 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,939 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| psoriasisSignal | 167 | 22.1 | 19.2 | 3,355 |
| skin exfoliationSignal | 49 | 10.0 | 7.6 | 390 |
| dry skinSignal | 54 | 7.0 | 5.4 | 272 |
| product use in unapproved indicationSignal | 87 | 6.1 | 4.9 | 366 |
| pruritusSignal | 113 | 5.1 | 4.3 | 372 |
| drug ineffectiveSignal | 253 | 3.3 | 3.0 | 433 |
| rashSignal | 80 | 3.2 | 2.6 | 119 |
| coughSignal | 51 | 3.1 | 2.4 | 73 |
| arthralgiaSignal | 65 | 2.7 | 2.1 | 69 |
| condition aggravatedSignal | 46 | 2.6 | 2.0 | 45 |
| painSignal | 72 | 2.0 | 1.6 | 37 |
| fatigue | 68 | 1.5 | 1.2 | 11 |
| diarrhoea | 48 | 1.3 | 1.0 | 3 |
| nausea | 48 | 1.0 | 0.8 | 0 |
| off label use | 50 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.